HAEMONETICS CORP's ticker is HAE and the CUSIP is 405024100. A total of 192 filers reported holding HAEMONETICS CORP in Q3 2013. The put-call ratio across all filers is - and the average weighting 0.2%.
Quarter-by-quarter ownership
Value | Shares | Weighting | ||||
---|---|---|---|---|---|---|
Q3 2023 | $45,184,421 | +2.8% | 504,403 | -2.3% | 0.01% | +25.0% |
Q2 2023 | $43,943,478 | +116.2% | 516,132 | +110.2% | 0.00% | +100.0% |
Q1 2023 | $20,323,236 | +7.3% | 245,598 | +2.0% | 0.00% | 0.0% |
Q4 2022 | $18,946,157 | -28.2% | 240,892 | -32.4% | 0.00% | -50.0% |
Q3 2022 | $26,374,000 | +9.6% | 356,252 | -3.5% | 0.00% | +33.3% |
Q2 2022 | $24,058,000 | -13.9% | 369,105 | -16.5% | 0.00% | -25.0% |
Q1 2022 | $27,941,000 | +20.0% | 441,955 | +0.7% | 0.00% | +33.3% |
Q4 2021 | $23,275,000 | +68.8% | 438,840 | +124.6% | 0.00% | +50.0% |
Q3 2021 | $13,790,000 | -69.9% | 195,356 | -71.6% | 0.00% | -66.7% |
Q2 2021 | $45,872,000 | -28.7% | 688,353 | +18.8% | 0.01% | -33.3% |
Q1 2021 | $64,347,000 | -22.0% | 579,662 | -16.6% | 0.01% | -30.8% |
Q4 2020 | $82,502,000 | +32.5% | 694,746 | -2.7% | 0.01% | +8.3% |
Q3 2020 | $62,285,000 | +57.1% | 713,861 | +61.2% | 0.01% | +33.3% |
Q2 2020 | $39,653,000 | +712.9% | 442,752 | +804.5% | 0.01% | +800.0% |
Q1 2020 | $4,878,000 | -89.4% | 48,948 | -87.8% | 0.00% | -90.9% |
Q4 2019 | $46,042,000 | +453.9% | 400,708 | +508.1% | 0.01% | +450.0% |
Q3 2019 | $8,312,000 | +32.1% | 65,897 | +26.0% | 0.00% | 0.0% |
Q2 2019 | $6,292,000 | -75.6% | 52,293 | -82.3% | 0.00% | -71.4% |
Q1 2019 | $25,816,000 | +50.8% | 295,118 | +72.5% | 0.01% | +40.0% |
Q4 2018 | $17,118,000 | -44.4% | 171,090 | -36.3% | 0.01% | -37.5% |
Q3 2018 | $30,770,000 | -7.8% | 268,544 | -27.8% | 0.01% | -11.1% |
Q2 2018 | $33,367,000 | +180.4% | 372,062 | +128.8% | 0.01% | +200.0% |
Q1 2018 | $11,898,000 | +4.1% | 162,623 | -17.4% | 0.00% | 0.0% |
Q4 2017 | $11,434,000 | +180.9% | 196,854 | +116.9% | 0.00% | +200.0% |
Q3 2017 | $4,071,000 | -66.9% | 90,749 | -70.9% | 0.00% | -75.0% |
Q2 2017 | $12,300,000 | +87.8% | 311,454 | +92.9% | 0.00% | +300.0% |
Q1 2017 | $6,548,000 | -50.1% | 161,442 | -50.5% | 0.00% | -50.0% |
Q4 2016 | $13,122,000 | +927.6% | 326,410 | +825.6% | 0.00% | – |
Q3 2016 | $1,277,000 | -30.9% | 35,264 | -44.7% | 0.00% | -100.0% |
Q2 2016 | $1,849,000 | +263.3% | 63,754 | +337.1% | 0.00% | – |
Q1 2016 | $509,000 | -85.0% | 14,585 | -86.1% | 0.00% | -100.0% |
Q4 2015 | $3,392,000 | -51.2% | 105,217 | -51.1% | 0.00% | -66.7% |
Q3 2015 | $6,954,000 | +255.5% | 215,140 | +354.8% | 0.00% | +200.0% |
Q2 2015 | $1,956,000 | +19.0% | 47,302 | +29.3% | 0.00% | 0.0% |
Q1 2015 | $1,644,000 | +133.5% | 36,578 | +94.5% | 0.00% | – |
Q4 2014 | $704,000 | -36.7% | 18,803 | -40.9% | 0.00% | – |
Q3 2014 | $1,112,000 | +14.8% | 31,839 | +15.9% | 0.00% | – |
Q2 2014 | $969,000 | -78.7% | 27,467 | -80.3% | 0.00% | -100.0% |
Q1 2014 | $4,548,000 | +488.4% | 139,545 | +661.3% | 0.00% | – |
Q4 2013 | $773,000 | -21.6% | 18,329 | -25.9% | 0.00% | – |
Q3 2013 | $986,000 | -63.7% | 24,739 | -62.4% | 0.00% | -100.0% |
Q2 2013 | $2,719,000 | – | 65,760 | – | 0.00% | – |
Download |
Other shareholders
Name | Shares | Value | Weighting ↓ |
---|---|---|---|
Millrace Asset Group, Inc. | 19,264 | $1,726 | 2.13% |
Parkman Healthcare Partners LLC | 88,962 | $7,969,216 | 1.46% |
HEARTLAND ADVISORS INC | 256,414 | $24,435,274 | 1.37% |
Riverwater Partners LLC | 15,553 | $1,393,238 | 1.27% |
KINGDON CAPITAL MANAGEMENT, L.L.C. | 111,100 | $9,952,338 | 1.15% |
Lisanti Capital Growth, LLC | 78,425 | $7,025,312 | 1.11% |
Aristotle Capital Boston, LLC | 311,666 | $27,919,054 | 0.90% |
ROYCE & ASSOCIATES LP | 947,550 | $84,881,529 | 0.86% |
CHASE INVESTMENT COUNSEL CORP | 18,770 | $1,681 | 0.84% |
Virtus Investment Advisers, Inc. | 13,662 | $1,223,842 | 0.83% |